Home > Homepage Original

Building a healthier
Tomorrow

for people with progressive non-viral liver diseases.

Learn more about OUR FOCUS >

Latest News

Sep 26, 2023
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
VIEW ALL PRESS RELEASES >

Exploring Racial Differences and Disparities in PBC Care

Hear provider and patient perspectives from a multidisciplinary roundtable discussion
conducted in the U.S.
VIEW THE ROUNDTABLE >

Meet Ally

Ally is a mother, teacher, and motorcycle enthusiast living with liver disease.
She is also our inspiration.

OUR STORY

Since 2002, we’ve pioneered a novel scientific platform to answer critical needs in the liver health community.

Medical Information

If you are a healthcare professional and have a medical inquiry, visit our Medical Information website.

US-NP-N/A-0137